8-K: Processa Pharmaceuticals Expands NGC-Cap Program into Advanced Breast Cancer Following FDA Agreement

Processa Pharmaceuticals will expand its Next Generation Capecitabine (NGC-Cap) program into advanced or metastatic breast cancer, with the FDA agreeing that existing data can support the Phase 2 trial design.

Summary

• Processa Pharmaceuticals is expanding its NGC-Cap program to include advanced or metastatic breast cancer.
• The FDA has agreed that existing data and studies can be used to support the Phase 2 breast cancer trial design.
• This expansion is considered a logical progression due to the larger market size of breast cancer compared to colorectal cancer.
• The company believes this approach will lead to a more efficient development program and a greater likelihood of FDA approval.
• The Phase 2 trial is expected to provide safety and efficacy data demonstrating the benefit of NGC-Cap over existing treatments.
• The company plans to initiate the Phase 2 study in the third quarter of 2024.
• Breast cancer is the most diagnosed cancer, representing approximately 15% of all new cancer patients in 2023.
• The potential market for NGC-Cap in breast, colorectal, and other cancers is estimated to be greater than 250,000 patients per year.

Sentiment

Score: 8

Explanation: The document is positive due to the FDA agreement, expansion into a larger market, and the potential for a more efficient development path. The company is moving forward with a clear plan and timeline.

Positives

• The FDA's agreement to use existing data for the Phase 2 trial significantly streamlines the development process.
• The expansion into breast cancer targets a larger market than the previously considered colorectal cancer.
• The company believes this approach will lead to a more efficient development program and a greater likelihood of FDA approval.
• The Phase 2 trial is expected to provide safety and efficacy data demonstrating the benefit of NGC-Cap over existing treatments.
• The company has identified breast cancer key opinion leaders to join their scientific advisory board.

Risks

• The document contains forward-looking statements which involve risks and uncertainties.
• Actual future performance outcomes and results may differ materially from those expressed in forward-looking statements.
• The company's SEC filings identify important risk factors which could cause actual results to differ from those contained in the forward-looking statements.

Future Outlook

The company plans to initiate a Phase 2 study in breast cancer in the third quarter of 2024, with the goal of demonstrating the benefit of NGC-Cap over existing treatments.

Management Comments

• The FDA and Processa discussed the advantages and disadvantages of developing NGC-Cap in breast cancer and concluded that the development would be a more efficient and straightforward path to approval with an easier enrolment process for the Phase 2 and 3 trials, said David Young, PharmD, Ph.D., President of Research and Development at Processa.
• We believe our Phase 2 trial will provide the safety-efficacy data to preliminarily demonstrate the benefit of NGC-Cap over capecitabine and other treatment options, concluded Young.

Industry Context

This announcement reflects a strategic shift towards a larger market opportunity in breast cancer, aligning with the industry's focus on developing more effective and safer cancer treatments. The use of existing data to support a Phase 2 trial is also a trend in the industry to accelerate drug development.

Comparison to Industry Standards

• The expansion into breast cancer is a common strategy for oncology companies seeking to address large patient populations.
• The use of existing data to support a Phase 2 trial is a strategy that is becoming more common in the industry to accelerate drug development.
• The company's approach of modifying existing FDA-approved drugs is a common strategy to reduce development risk and time.

Stakeholder Impact

• Shareholders may view this as positive news due to the larger market opportunity and streamlined development process.
• Patients with advanced or metastatic breast cancer may benefit from a new treatment option.
• Employees may be impacted by the increased workload associated with the new trial.

Next Steps

• The company will share the Phase 2 study design with the FDA soon.
• The company plans to initiate the Phase 2 study in the third quarter of 2024.

Key Dates

Keywords

NGC-Cap, breast cancer, FDA, Phase 2 trial, capecitabine, metastatic cancer, chemotherapy, Processa Pharmaceuticals, PCS6422, oncology